NEW YORK, Feb. 27, 2024 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital today announced the addition of David Epstein to its Healthcare Advisory Board. Mr. Epstein was CEO of Seagen before closing its sale to Pfizer in December 2023. David previously served as Executive Partner at Flagship Pioneering as well as CEO of Novartis Pharmaceuticals. His 30 years of industry experience includes drug development, deal making, venture investing, commercialization, and leadership experience on a global scal ...